Impilo
Stockholm, SwedenImpilo is a Nordic healthcare-focused investment company founded in 2017 by former Altor partners Fredrik Stromholm and Jesper Eliasson, based in Stockholm with a second office in Copenhagen. It targets majority and large-minority investments in pharmaceutical, medtech, specialist pharma services and healthcare services companies with enterprise values of roughly EUR 50m to 200m across the Nordics. Impilo has raised about EUR 2bn since inception through two SEK investment pools and its first euro-denominated closed-end vehicle, Fund II, which closed at its EUR 700m hard cap in June 2025.
Impilo is a Stockholm buyout firm with €2.0B AUM, 13 active companies and 4 exits.
- ·3 exits in the last 5 years · consistent DPI cadence.
- ·Average hold across 4 realized deals: 5 years.
- ·Top sector focus: MedTech (41% of portfolio).
- ·Fund cadence: ~4Y between vintages · last raise 2025.
Sector breakdown
17 companiesGeography breakdown
4 geographiesKey facts
Recent exits
Impilo sold Ferrosan Medical Devices to Kirk Kapital, Lundbeckfonden and ATP in 2024 after 7 years.
Impilo sold TFP Fertility to Benefit Street Partners in 2024 after 5 years.
Impilo sold NutraQ to Orkla in 2021 after 4 years.
Impilo sold Cavidi to Original founders in 2020 after 2 years.
Coverage notes
3 funds tracked, 17 portfolio companies (13 active · 4 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Impilo has raised, with its portfolio companies. Hand-checked from public filings.
Impilo Fund IIBuyout2025€700M1 assetsBuyout2025 · 1yr€700M1–
Unrealized
1 held| Company | Entry |
|---|---|
| Oticon Medical MedTech · Sweden | 2025 |
Impilo Investment Pool 2Buyout2021€590M9 assetsBuyout2021 · 5yr€590M9–
Unrealized
9 held| Company | Entry |
|---|---|
| Avia Pharma Pharma · Sweden | 2024 |
| Decon MedTech · Sweden | 2023 |
| Lowenco MedTech · Denmark | 2022 |
| Pelago Bioscience Pharma · Sweden | 2023 |
| Qufora MedTech · Denmark | 2024 |
| Scantox Pharma · Denmark | 2021 |
| Stille MedTech · Sweden | 2023 |
| Tandlaegen.dk Healthcare · Denmark | 2024 |
| VaccinDirekt Healthcare · Sweden | 2023 |
Impilo Investment Pool 1HarvestingBuyout20183 assets4 exitsBuyout2018 · 8yr–34
Unrealized
3 held| Company | Entry |
|---|---|
| Euro Accident Financials · Sweden | 2019 |
| Humana Healthcare · Sweden | 2019 |
| Immedica Pharma · Sweden | 2018 |
Realized
4 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Cavidi MedTech · Sweden | 2018 | 2020 | MBO | Original founders | – |
| Ferrosan Medical Devices MedTech · Denmark | 2017 | 2024 | Trade Sale | Kirk Kapital, Lundbeckfonden and ATP | – |
| NutraQ Consumer · Norway | 2017 | 2021 | Trade Sale | Orkla | – |
| TFP Fertility Healthcare · UK | 2019 | 2024 | Secondary | Benefit Street Partners | – |
Frequently asked questions
- What investment strategy does Impilo focus on?
- Impilo focuses on Buyout, Growth strategies in the private equity space.
- How many portfolio companies does Impilo have?
- Impilo has 13 active portfolio companies and 4 completed exits and 3 funds tracked on GP Intel.
- Where is Impilo headquartered?
- Impilo is headquartered in Stockholm, Sweden.
- What is Impilo's assets under management?
- Impilo manages approximately €2.0B in assets under management.
- When was Impilo founded?
- Impilo was founded in 2017.
- What sectors does Impilo invest in?
- Impilo invests across Healthcare.
- What are Impilo's recent exits?
- Recent realized exits by Impilo include: Ferrosan Medical Devices (2024) to Kirk Kapital, Lundbeckfonden and ATP; TFP Fertility (2024) to Benefit Street Partners; NutraQ (2021) to Orkla; Cavidi (2020) to Original founders.
Similar firms
Other private equity firms tracked on GP Intel.
